• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [17290 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2018     Center for Evidence-based Practice (CEP) The Effect of Electronic Medical Record Alerts on Provider Wellness
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk. Update 2018
2018     NIHR Health Technology Assessment programme A randomised controlled trial and economic evaluation of intraoperative cell salvage during caesarean section in women at risk of haemorrhage: the SALVO (cell SALVage in Obstetrics) trial
2018     Health Quality Ontario (HQO) Bilateral Cochlear Implantation: A Health Technology Assessment
2018     Center for Evidence-based Practice (CEP) Palliative care in the outpatient setting for patients with heart failure or advanced lung disease
2018     Center for Evidence-based Practice (CEP) Management structures for hospital nursing
2018     Center for Evidence-based Practice (CEP) Treatment of severe acute medical-psychiatric comorbidity in hospitalized patients
2018     Center for Evidence-based Practice (CEP) Diagnosis and treatment of gastrointestinal bleeding in patients with left ventricular assist devices
2018     Center for Evidence-based Practice (CEP) Cognitive therapy for schizophrenia
2018     Andalusian Health Technology Assessment Area (AETSA) Electrical stimulation of peripheral nerves for treating chronic refractory pain
2018     Center for Evidence-based Practice (CEP) Nurse-directed discontinuation of continuous ECG monitoring among non-ICY inpatients
2018     Andalusian Health Technology Assessment Area (AETSA) [Digital tomosynthesis in breast cancer: meta-analysis]
2018     Andalusian Health Technology Assessment Area (AETSA) Bibliographic review on the diagnosis, treatment and follow-up of Kawasaki disease
2018     Andalusian Health Technology Assessment Area (AETSA) 18F-FDG PET in early diagnosis of degenerative diseases of the central nervous system
2018     Andalusian Health Technology Assessment Area (AETSA) Prognostic genomic tests in early breast cancer: up-date of evidence.
2018     Andalusian Health Technology Assessment Area (AETSA) Alectinib as monotherapy for the firstline treatment of adult patients with ALKpositive advanced non-small cell lung cancer. EUnetHTA adopted HTA report
2018     Andalusian Health Technology Assessment Area (AETSA) Midostaurin with standard chemotherapy in FLT3-positive acute myeloid leukaemia. EUnetHTA adopted HTA report.
2018     Andalusian Health Technology Assessment Area (AETSA) Quality criteria and good practices in organizations dedicated to the Health Technologies Assessment
2018     Andalusian Health Technology Assessment Area (AETSA) Regorafenib indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib. EUnetHTA adopted HTA report.
2018     Health Quality Ontario (HQO) Portable ultraviolet light surface-disinfecting devices for prevention of hospital-acquired infections: a healthtechnology assessment
2018     Health Quality Ontario (HQO) Continuous monitoring of glucose for Type 1 Diabetes: a health technology assessment
2018     Health Quality Ontario (HQO) Portable ultraviolet light surface-disinfecting devices for prevention of hospital-acquired infections: OHTAC recommendation
2018     Adelaide Health Technology Assessment (AHTA) Pharmaceutical Benefits Scheme post-market review of Pulmonary Arterial Hypertension medicines
2018     Health Quality Ontario (HQO) Continuous monitoring of glucose for Type 1 diabetes: OHTAC recommendation
2018     Adelaide Health Technology Assessment (AHTA) Processing and cryopreservation of ovarian tissue prior to or after gonadotoxic treatment to preserve fertility in females for the future
2018     Adelaide Health Technology Assessment (AHTA) Systematic literature review on the association between alcohol consumption and mental health disorders. Evidence Evaluation Report
2018     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [TIDY program. Therapeutic Identification of depression in Young people.]
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC)
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)
2018     Health Technology Wales (HTW) Epithelium-off corneal crosslinking to treat adults with keratoconus
2018     Health Technology Wales (HTW) Sacral nerve stimulation to treat faecal incontinence that cannot be controlled with conservative management
2018     Health Technology Wales (HTW) FreeStyle Libre flash glucose monitoring for the management of type 1 or type 2 diabetes
2018     NIHR Health Technology Assessment programme Combining optical coherence tomography with visual field data to rapidly detect disease progression in glaucoma: a diagnostic accuracy study
2018     Center for Evidence-based Practice (CEP) Acid Suppression Therapy for Oncology Patients
2018     Health Technology Wales (HTW) Mechanical chest compression for use by the ambulance service to treat adults with out-of-hospital non-traumatic cardiac arrest
2018     Belgian Health Care Knowledge Centre (KCE) Responsible use of high-risk medical devices: the example of 3D printed medical devices
2018     Health Technology Wales (HTW) Faecal immunochemical test-based prediction tools for the assessment of people presenting to primary care with symptomatic bowel disease
2018     National Authority for Assessment and Accreditation in Healthcare (INEAS) Le trastuzumab dans le traitement du cancer du sein HER2 positif au stade précoce et localement avancé 
2018     Health Quality Ontario (HQO) Internet-Delivered Cognitive Behavioural Therapy for Major Depression and Anxiety Disorders: A Health Technology Assessment
2018     Health Quality Ontario (HQO) Remote Monitoring of Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy and Permanent Pacemakers: A Health Technology Assessment
2018     Health Quality Ontario (HQO) Magnetic Resonance-Guided Focused Ultrasound Neurosurgery for Essential Tremor: A Health Technology Assessment
2018     Health Quality Ontario (HQO) Structured Education and Neuromuscular Exercise Program for Hip and/or Knee Osteoarthritis: A Health Technology Assessment
2018     Adelaide Health Technology Assessment (AHTA) Systematic literature review on the association between alcohol consumption and mental health disorders. Technical Report
2018     Health Quality Ontario (HQO) Electronic Monitoring Systems to Assess Urinary Incontinence: A Health Technology Assessment
2018     NIHR Health Technology Assessment programme The UK EndoVascular Aneurysm Repair (EVAR) randomised controlled trials: long-term follow-up and cost-effectiveness analysis
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Echocardiography: Guideline recommendations and options to identify inappropriate use as well as usage rate in Austria
2018     Basque Office for Health Technology Assessment (OSTEBA) [HIFU —High intensity focused ultrasound— in essential tremor]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of the scientific evidence on nipple-areola complex micropigmentation, requirements for its proper implementation and costs]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Immunological faecal occult blood test for patients with symptoms compatible with colorectal cancer: recommendation of Clinical Practice Guides and use in the National Health System]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Radiofrequency tonsil reduction]
2018     Basque Office for Health Technology Assessment (OSTEBA) [Effectiveness and safety of bone suppression technology for the detection of lung cancer and indications for its use]
2018     NIHR Health Technology Assessment programme PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer
2018     Basque Office for Health Technology Assessment (OSTEBA) [Strategies for promoting and strengthening evidence-based nursing in the Basque Country]
2018     Belgian Health Care Knowledge Centre (KCE) MammaPrint® test for personalised management of adjuvant chemotherapy decisions in early breast cancer
2018     Basque Office for Health Technology Assessment (OSTEBA) [Checklist for ethical and legal domains analysis]
2018     NIHR Health Services and Delivery Research programme Understanding new models of integrated care in developed countries: a systematic review
2018     NIHR Health Services and Delivery Research programme A staff training intervention to improve communication between people living with dementia and health-care professionals in hospital: the VOICE mixed-methods development and evaluation study
2018     NIHR Health Technology Assessment programme Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review
2018     NIHR Health Technology Assessment programme What works to increase attendance for diabetic retinopathy screening? An evidence synthesis and economic analysis
2018     NIHR Health Technology Assessment programme The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisation
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Optimal use guide: antibiotic prophylaxis during clean orthopedic surgery in children and adults]
2018     NIHR Health Technology Assessment programme Screening women aged 65 years or over for abdominal aortic aneurysm: a modelling study and health economic evaluation
2018     NIHR Health Technology Assessment programme Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis
2018     NIHR Health Technology Assessment programme Therapeutic hypothermia to reduce intracranial pressure after traumatic brain injury: the Eurotherm3235 RCT
2018     NIHR Health Technology Assessment programme Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis
2017     NIHR Health Technology Assessment programme A randomised controlled study of the effectiveness of breathing retraining exercises taught by a physiotherapist either by instructional DVD or in face-to-face sessions in the management of asthma in adults
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lonoctocog alfa (haemophilia A) - benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma, first-line treatment) - benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme Clinical effectiveness and cost-effectiveness of surgical options for the management of anterior and/or posterior vaginal wall prolapse: two randomised controlled trials within a comprehensive cohort study results from the PROSPECT Study
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (non-small cell lung cancer) - benefit assessment according to §35a Social Code Book V ]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma) - benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixekizumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme A multicentre, randomised controlled trial of position during the late stages of labour in nulliparous women with an epidural: clinical effectiveness and an economic evaluation (BUMPES)
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Secukinumab (plaque psoriasis) - benefit assessment according to §35a Social Code Book V (new scientific findings)]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - addendum to order A16-69]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Elosulfase alfa (mucopolysaccharidosis type IVA) - assessment according to §35a (para. 1, sentence 11) Social Code Book V (new scientific findings)]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Palbociclib (breast cancer) - addendum to commission A16-74]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Obeticholic acid (primary biliary cholangitis) – assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ixazomib (multiple myeloma) – assessment according to § 35a (para. 1, sentence 10) Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Procedure for lung volume reduction in severe lung emphysema]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Analysis of clinical studies of medical devices]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extracorporeal shock wave therapy (ESWT) for heel pain]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the pancreas – addendum to commission H16-02C]
2017     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: organization of the continuum and provision of services to children aged 2 to 9 years with specific language impairment]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Active knee motion devices in the treatment of anterior cruciate ligament ruptures]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for secondary malignant neoplasms of the liver and the intrahepatic bile ducts – addendum to commission H16-02E]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Guideline synopsis for a DMP "Depression"]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Update of the guideline synopsis for the DMP "rheumatoid arthritis" - rapid report]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ribociclib (breast cancer) - benefit assessment according to §35a Social Code Book V]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pembrolizumab (urothelial carcinoma) - benefit assessment according to §35a Social Code Book V]
2017     NIHR Health Technology Assessment programme Support and Assessment for Fall Emergency Referrals (SAFER) 2: a cluster randomised trial and systematic review of clinical effectiveness and cost-effectiveness of new protocols for emergency ambulance paramedics to assess older people following a fall with referral to community-based care when appropriate
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Angiogenesis inhibitors (bevacizumab - ranibizumab) in neovascular glaucoma and corneal neovascularization]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darunavir-cobicistat-emtricitabine-tenofovir alafenamide (HIV infection) - benefit assessment according to §35a Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Bariatric surgery as treatment for obesity in subjects over 65 years old]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Avelumab (metastatic Merkel cell carcinoma) - benefit assessment according to §35a (1), sentence 11, Social Code Book V]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) Bariatric surgery to treat obesity in individuals under 21 years old
2017     HAYES, Inc. Dorsal root ganglion stimulation for the treatment of complex regional pain syndrome
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Usefulness of N-terminal type B natriuretic propeptide in amyloidosis]
2017     HAYES, Inc. Flexitouch system (Tactile Systems Technology Inc.) for lymphedema
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Dynamic magnetic resonance imaging in pelvic floor dysfunction]